Anda di halaman 1dari 5

Published on Novartis (https://www.novartis.

com)
Home > Printer-friendly PDF > Clinical Pipeline

Clinical Pipeline
Novartis is consistently rated as having one of the industrys most respected development
pipelines, with more than 200 projects in clinical development.
Many of these projects, which include new molecular entities as well as additional indications
and different formulations for marketed products, are for medicines that could significantly
advance treatment standards for patients worldwide. This table provides an overview of
selected projects in development.
For a detailed review of selected projects in confirmatory development, download the
complete Novartis Pipeline (PDF 84 KB), as of December 31, 2015.

Planned Filings - Pharmaceuticalsa


molecule-yellow.png
New Molecule
molecule-orange.png
New Indication
molecule-maroon.png
New Formulation
biosimilar-01-20x20.png
Biosimilars

Accordion:
2016
Type

moleculeyellow.png

Project

Potential Indication/Disease Area

LEE011 + ltz

HR+, HER2 (-) postmenopausal Adv.


Breast Cancer 1st line

moleculemoleculeyellow.png
moleculeorange.png
moleculeorange.png
orange.png
moleculeorange.png
moleculemoleculeorange.png
orange.png
moleculeorange.png
moleculeorange.png
moleculemaroon.png
biosimilar-01biosimilar-0120x20.png
biosimilar-0120x20.png
20x20.png

PKC412
Afinitor/Votubia b
Arzerra c
Ilaris c

Acute myeloid leukemia


Tuberous sclerosis complex seizures
Chronic Lymphocytic Leukemia (relapsed)
Periodic fever syndromes
Choroidal neovascularization (CNV)

b
Lucentis
secondary to conditions other than macular
degeneration and pathologic myopia
PKC412
Aggressive systemic mastocytosis

Tafinlar + Mekinist BRAF V600+ non-small cell lung cancer


Chronic myeloid leukemia treatment free
Tasigna b
remission

Votrient
Renal cell carcinoma (adjuvant)

Signifor Long
Cushings disease
Acting Release
Adalimumab (US)
GP2017
Epoetin-alfa (US)
HX575
b
Rituximab (EU)
GP2013

2017
Type

moleculeyellow.png
moleculeyellow.png
moleculeyellow.png
moleculeorange.png
moleculemoleculeorange.png
orange.png
moleculeorange.png
moleculeorange.png
biosimilar-01biosimilar-0120x20.png
biosimilar-0120x20.png
20x20.png
2018

Project

Potential Indication/Disease Area

CTL019

Pediatric acute lymphoblastic leukemia


Neovascular age-related macular
degeneration
Acute heart failure
Secondary prevention of cardiovascular
events
Diffuse large B-cell lymphoma
Pediatric Multiple Sclerosis

OAP030d
RLX030
ACZ885
CTL019
FTY720
Tafinlar + Mekinist

BRAF V600+ Melanoma (adjuvant)

ZykadiaTM

ALK+ adv. Non-small cell lung cancer (1


st line, treatment naive)
GP2013
GP2017
GP1111

Rituximab (US)
Adalimumab (EU)
Infliximab (EU)

Type

moleculemoleculeyellow.png
yellow.png
moleculeyellow.png
moleculemoleculeorange.png
orange.png
moleculeorange.png
moleculeorange.png
moleculemoleculeorange.png
orange.png

Project

Potential Indication/Disease Area

INC280
LCI699

Non-small cell lung cancer


Cushings Disease
Neovascular age-related macular
degeneration
Non-Hodgkin's lymphoma (refractory)
Non-radiographic axial spondyloarthritis
HR+, HER2(-) postmenopausal adv.
Breast Cancer 1st/2nd line
HR+, HER2(-) premenopausal adv.
Breast Cancer 1st line
Asthma
Asthma

RTH258
Arzerra
Cosentyx
LEE011+ fulv
LEE011+ tmx +
gsn/or NSAI + gsn
QMF149
QVM149

2019
Type

Project

Potential Indication/Disease Area

BAF312

moleculeyellow.png
moleculeyellow.png
moleculemoleculeyellow.png
moleculeorange.png
moleculeorange.png
moleculeorange.png
orange.png
molecule? 2020
orange.png

Secondary progressive multiple sclerosis


HR+, HER2 (-) postmenopausal adv. Breast
BYL719 + fulv
Cancer 2nd line
QAW039
Asthma
TM
Entresto
Heart Failure (Preserved ejection fraction)

Jakavi
Graft-Versus-Host Disease
Lucentis
Retinopathy of prematurity
OMB157
Relapsing multiple sclerosis
ALK+ Non-small cell lung cancer (Brain
ZykadiaTM
metastases)

Type

Project

ABL001
molecule-yellow.png ASB183
molecule-yellow.png BGJ398
molecule-yellow.png BYM338
molecule-yellow.png BKM120
molecule-yellow.png CAD106

molecule-yellow.png

Potential Indication/Disease Area


Chronic myeloid leukemia
Solid and hematologic tumors
Solid tumors
Hip fracture
Solid tumors
Alzheimers disease

CJM112
molecule-yellow.png CNP520
molecule-yellow.png EMA401
molecule-yellow.png FCR001
molecule-yellow.png HSC835
molecule-yellow.png KAE609
molecule-yellow.png KAF156
molecule-yellow.png LIK066
molecule-yellow.png LJM716
molecule-yellow.png LJN452
molecule-yellow.png PIM447
molecule-yellow.png QAX576

molecule-yellow.png QGE031
molecule-yellow.png VAY736
molecule-yellow.png BYL719
BYM338
moleculeEntrestoTM
moleculeorange.png
Jakavi
moleculeorange.png
LEE011
moleculeorange.png
QAW039
moleculeorange.png
RTH258
moleculeorange.png
Tafinlar +
moleculeorange.png
Mekinist
orange.png
moleculeorange.png
Disclaimer:

Immune disorders
Alzheimers disease
Neuropathic pain
Renal transplantation
Stem cell transplantation
Malaria
Malaria
Metabolic disorders
Solid tumors
Non-alcoholic steatohepatitis
Hematologic tumors
Allergic diseases
Chronic spontaneous urticaria /
inducible urticaria
Primary Sjoegren's syndrome
Solid tumors
Sarcopenia
Post-acute myocardial infarction
Early myelofibrosis
Solid tumors
Atopic dermatitis
Diabetic macular edema
BRAF V600+ Colorectal cancer

This information was factually accurate on the date it was published. Novartis assumes no
duty to update the information to reflect subsequent developments. Readers should not rely
upon the information on this page as current or accurate after its publication date. For the
latest information on the Novartis' pipeline, readers should visit the News [1] and Investors [2]
sections of our website. This information constitutes forward-looking statements relating to
Novartis AG's business, including express or implied discussions regarding potential new
products, potential new indications for existing products, or regarding potential future
revenues from any such products. Such forward-looking statements reflect the current views
of Novartis AG regarding future events, and involve known and unknown risks, uncertainties
and other factors that may cause actual results to be materially different from any future
results, performance or achievements expressed or implied by such statements. There can be
no guarantee that any new products will be approved for sale in any market, or that any new
indications will be approved for existing products in any market, or that such products will
achieve any particular revenue levels. In particular, management's expectations could be
affected by, among other things, uncertainties involved in the development of new
pharmaceutical products; unexpected clinical trial results, including additional analysis of
existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays
or government regulation generally; the Novartis Group's ability to obtain or maintain patent or
other proprietary intellectual property protection, including the uncertainties involved in the US
litigation process; competition in general; government, industry, and general public pricing and
other political pressures; and other risks and factors referred to in Novartis AG's current Form

20-F on file with the US Securities and Exchange Commission. Should one or more of these
risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual
results may vary materially from those described herein as anticipated, believed, estimated or
expected.
Footnotes:
Combination Abbreviations:
fulv - fulvestrant
ltz - letrozole
tmx - tamoxifen
gsn - goserelin
NSAI - Non-steroidal aromatase inhibitor

AMG 334 is not included in this view. AMG 334 is part of the global collaboration with
Amgen to commercialize and develop neuroscience treatments.
b Submitted in EU.
c Submitted in US and EU.
Also known as Fovista (pegpleranib) and E10030. This product is being developed by
d Ophthotech Corp. Ophthotech has licensed ex-US commercialization rights to Novartis
under a Licensing and Commercialization Agreement.
a

Source URL: https://www.novartis.com/our-work/research-development/clinical-pipeline


Links
[1] https://www.novartis.com/news
[2] https://www.novartis.com/investors